Annexon, Inc. Presents Promising Data from Phase 2 ARCHER Study

Annexon, Inc. (NASDAQ:ANNX) recently shared exciting developments from its Phase 2 ARCHER study regarding ANX007 and its impact on geographic atrophy due to dry age-related macular degeneration. The company released a press statement on October 21, 2024, known as the AAO Press Release, highlighting the latest findings.

According to the report, ANX007 exhibited substantial vision protection and significant preservation of central photoreceptor cells in a specific subset of patients with less advanced disease, as reflected by the photoreceptor ellipsoid zone in the central fovea. This significant data was unveiled at the American Academy of Ophthalmology (AAO) 2024 annual meeting.

A detailed account of these findings can be accessed through the AAO Press Release, which has been officially disclosed as Exhibit 99.1 and is now part of the public record for reference.

In addition to this, Annexon, Inc. also filed Exhibit 104.1, covering an Interactive Data File in inline XBRL format.

The company concluded this filing with the required signatures, affirming the accuracy and validity of the information provided. As per the signatories, this report was officially endorsed on behalf of Annexon, Inc. on October 21, 2024, by Jennifer Lew, the Executive Vice President and Chief Financial Officer of the organization.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Annexon’s 8K filing here.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.